The global vulvovaginal candidiasis treatment market, currently valued at USD 1,035 million in 2023, is poised for steady growth over the next decade. With a projected Compound Annual Growth Rate (CAGR) of 4.5%, the market is expected to reach an estimated valuation of USD 1,607 million by 2033.
This growth is being driven by technological advancements in the healthcare sector, leading to more effective and accessible treatments for vulvovaginal candidiasis (VVC), a common fungal infection affecting millions of women worldwide. Innovations in antifungal therapies, along with increasing awareness and diagnosis rates, are key contributors to the market’s expansion.
As healthcare providers continue to adopt new diagnostic tools and treatment options, the market for vulvovaginal candidiasis treatment is expected to see sustained demand and investment.
The high growth rate can be attributed to the rising disease burden of VVC and increasing testing rates. Positive changes, such as healthcare benefits by the government, increased awareness among consumers, and willingness to avail medical treatments are also expected to drive the growth of the vulvovaginal candidiasis treatment market.
Rapid increase in the global disease burden, coupled with escalating demand for better treatment options and increasing number of hospital-acquired infections, is also propelling the demand for bacterial vulvovaginal candidiasis treatment.
Furthermore, expanding healthcare infrastructure in developing economies, availability of pharmaceutical drugs, and robust technological advancements in the biopharmaceutical industries are all contributing to significant opportunities for vulvovaginal candidiasis treatment over the forecasted period.
Key Takeaways from the Market Study
- As of 2023, the vulvovaginal candidiasis treatment market was valued at US$ 1035 Million
- From 2023 to 2033, the industry is poised to grow at a 4.5% CAGR
- By 2033, vulvovaginal candidiasis treatment market is slated to reach a valuation of US$ 1607 Million
- By route of administration, the oral segment accounted for the largest share of 43.2% and is expected to continue this trend over the forecast period.
- China is poised to yield a CAGR of 4.2% with respect to vulvovaginal candidiasis treatment in 2033
“Increasing prevalence of VVC cases and technological advancement in healthcare are expected to radically transform the vulvovaginal candidiasis treatment market in the coming years,” comments an analyst at FMI.
Competitive Landscape
Astellas Pharma Inc., Mycovia Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd., Scynexis, Inc., Grupo Ferrer Internacional S.A., Pfizer, Inc.,Cadila Pharmaceuticals,Bayer AG., Bristol-Myers Squibb Company are some of the key companies in the vulvovaginal candidiasis treatment market.
These players are continuously adopting various strategies such as new product launches, facility expansions, mergers, collaborations, partnerships, and acquisitions to increase their revenue share and gain a competitive edge in the market. for instance,
- In October 2022 – Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation)*.
- In August 2022 – Mycovia Pharmaceuticals, Inc. announced that it will present VIVJOA
(oteseconazole) capsules in patients with recurrent vulvovaginal candidiasis (RVVC) at the 2022 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. VIVJOA is the first and only FDA-approved medication for RVVC indicated to reduce the incidence of RVVC in females with a history of RVVC who are NOT of reproductive potential - In July 2022 – Mycovia Pharmaceuticals, Inc. announced U.S. availability of VIVJOA (oteseconazole) capsules, an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
Key Segments Covered in the Vulvovaginal Candidiasis Treatment Market Industry Survey
Vulvovaginal Candidiasis Treatment Market by Drug Class:
- Clotrimazole
- Nystatin
- Fluconazole
- Ketoconazole
- Terbinafine
- Terconazole
- Others
Vulvovaginal Candidiasis Treatment Market by Route of Administration:
- Oral Vulvovaginal Candidiasis Treatment
- Intravenous Vulvovaginal Candidiasis Treatment
- Topical Vulvovaginal Candidiasis Treatment
Vulvovaginal Candidiasis Treatment Market by Distribution Channel:
- Hospital Pharmacy for Vulvovaginal Candidiasis Treatment
- Retail Pharmacy for Vulvovaginal Candidiasis Treatment
- Online Pharmacy for Vulvovaginal Candidiasis Treatment
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
